Anti-interleukin 17 use has been associated with a higher risk of candidiasis, as this cytokine is involved in maintaining mucosal barriers and orchestrating immune responses to fungal pathogens. We performed a real-life retrospective multicentre study aiming to assess the risk of candidiasis in patients undergoing treatment with bimekizumab at labelled dosage for psoriasis, for at least 16 weeks.
Megna, M., Orsini, D., Assorgi, C., Balato, A., Balestri, R., Bianchi, L., et al. (2025). The risk of candidiasis during treatment with bimekizumab for the management of plaque psoriasis: A 16-week multicentre real-world experience - IL PSO (Italian Landscape Psoriasis). CLINICAL AND EXPERIMENTAL DERMATOLOGY, 50(4 (April 2025)), 858-859 [10.1093/ced/llae400].
The risk of candidiasis during treatment with bimekizumab for the management of plaque psoriasis: A 16-week multicentre real-world experience - IL PSO (Italian Landscape Psoriasis)
Carugno, Andrea;
2025
Abstract
Anti-interleukin 17 use has been associated with a higher risk of candidiasis, as this cytokine is involved in maintaining mucosal barriers and orchestrating immune responses to fungal pathogens. We performed a real-life retrospective multicentre study aiming to assess the risk of candidiasis in patients undergoing treatment with bimekizumab at labelled dosage for psoriasis, for at least 16 weeks.
| File | Dimensione | Formato | |
|---|---|---|---|
|
Megna-2024-Clin Exp Dermatol-AAM.pdf
Solo gestori archivio
Tipologia di allegato:
Author’s Accepted Manuscript, AAM (Post-print)
Licenza:
Tutti i diritti riservati
Dimensione
204.13 kB
Formato
Adobe PDF
|
204.13 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
